Cancer, from kidney to melanomas: here are the targets of immunotherapy – Il Messaggero

Cancer, from kidney to melanomas: here are the targets of immunotherapy

The list of gods is growing visibly tumors that can be affected with immunotherapy, that is with the new approach that disables the signals with which the tumors deceive the immune system to grow undisturbed: from the most aggressive skin cancer, the melanoma, to that of the lung, then the breast tumors , including those that have hitherto been more resistant to treatment, and still head and neck tumors, bladder, kidney and Hodgkin's lymphoma.

«Immunotherapy will defeat tumors by 2050». The announcement of the Nobel Prize in Medicine

In Stockholm, there is enthusiasm among experts who have been convinced of the efficacy of this new approach for at least 30 years, awarded this year with the Nobel Prize for Medicine to the American James P. Allison and the Japanese Tasuku Honjo. "The Nobel award was the icing on the cake after three decades of activity that, despite the many failures, eventually led to recognize immunotherapy as the fourth strategy to fight cancer," noted the director of the center of Immuno – Oncology of the Siena Polyclinic, Michele Maio, in the meeting on immunotherapy organized today in Stockholm by the Roche Foundation and the Roche pharmaceutical company during the Nobel Week. "Now – added Maio – the bet is to identify the areas in which to work in the near future to improve the spectacular results achieved so far". This is why the experiments are multiplying all over the world, as Allison stressed today in his Nobel conference. The proteins discovered by Allison and Honjo are at the center of many experiments, along with many others identified later, and the experiments proceed at 360 degrees. We must also study the possibility of modifying the characteristics of the cancer cells, discovering the interface that allows them to communicate with the immune system, and to select in advance the tumors that have the right characteristics to respond to treatment. "We will continue to experiment for the next ten years. The story – concluded Maio – has just begun ».




Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.